Erik Koehne, Liesbeth Van Wesenbeeck, Martin L Hibberd, Annemie Buelens, Michiko Toizumi, Kim De Clerck, Leen Vijgen, Ole Lagatie, Lucy Masdin, Hien Anh Thi Nguyen, Hoang Huy Le, Duc Anh Dang, Mai Kim Huynh, Lien Thuy Le, Trieu Bao Nguyên, Stephane Hue, Hung Thai Do, Guillermo Herrera-Taracena, Freya Rasschaert, Lay-Myint Yoshida
{"title":"有症状的指数病例家庭接触者中的登革热感染：对社区干预研究的意义","authors":"Erik Koehne, Liesbeth Van Wesenbeeck, Martin L Hibberd, Annemie Buelens, Michiko Toizumi, Kim De Clerck, Leen Vijgen, Ole Lagatie, Lucy Masdin, Hien Anh Thi Nguyen, Hoang Huy Le, Duc Anh Dang, Mai Kim Huynh, Lien Thuy Le, Trieu Bao Nguyên, Stephane Hue, Hung Thai Do, Guillermo Herrera-Taracena, Freya Rasschaert, Lay-Myint Yoshida","doi":"10.3390/v17060859","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dengue is a global health concern, with half of the world's population at risk and no antiviral treatment available. This Phase 0 study investigated dengue infections among household contacts (HHCs) of dengue index cases (ICs) and assessed the feasibility of conducting a Phase 2 trial for a novel antiviral.</p><p><strong>Methods: </strong>Participants were enrolled in Nha Trang, Vietnam, from April 2022 to February 2023. Dengue ICs were identified within 72 h of fever onset, and their healthy adult HHCs enrolled within 48 h. Blood samples and questionnaires were collected bi-weekly for four weeks, with a follow-up visit on day 40. DENV RT-qPCR, NS1, and anti-DENV IgM/IgG ELISAs were performed.</p><p><strong>Results: </strong>Overall, 130 dengue ICs and 301 HHCs were enrolled, with 91.7% (276/301) completing all follow-up visits. Baseline anti-DENV IgG showed prior dengue infections in 262/301 HHCs (87.0%). Fifty HHCs were excluded from the HHC infection analysis based on evidence of a DENV infection (viral load [VL], NS1, IgM, and IgG results) at enrollment. During follow-up, 2.0% of HHCs (5/251) had DENV infections based on virological parameters (DENV RNA and/or NS1 positivity), and anti-DENV IgG/IgM seroconversion was detected in 7.2% (18/251).</p><p><strong>Conclusions: </strong>This study demonstrated the operational feasibility of a dengue IC-HHC design for a Phase 2 trial.</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 6","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197545/pdf/","citationCount":"0","resultStr":"{\"title\":\"Dengue Infections Among Household Contacts of Symptomatic Index Cases: Implications for Community-Based Intervention Studies.\",\"authors\":\"Erik Koehne, Liesbeth Van Wesenbeeck, Martin L Hibberd, Annemie Buelens, Michiko Toizumi, Kim De Clerck, Leen Vijgen, Ole Lagatie, Lucy Masdin, Hien Anh Thi Nguyen, Hoang Huy Le, Duc Anh Dang, Mai Kim Huynh, Lien Thuy Le, Trieu Bao Nguyên, Stephane Hue, Hung Thai Do, Guillermo Herrera-Taracena, Freya Rasschaert, Lay-Myint Yoshida\",\"doi\":\"10.3390/v17060859\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Dengue is a global health concern, with half of the world's population at risk and no antiviral treatment available. This Phase 0 study investigated dengue infections among household contacts (HHCs) of dengue index cases (ICs) and assessed the feasibility of conducting a Phase 2 trial for a novel antiviral.</p><p><strong>Methods: </strong>Participants were enrolled in Nha Trang, Vietnam, from April 2022 to February 2023. Dengue ICs were identified within 72 h of fever onset, and their healthy adult HHCs enrolled within 48 h. Blood samples and questionnaires were collected bi-weekly for four weeks, with a follow-up visit on day 40. DENV RT-qPCR, NS1, and anti-DENV IgM/IgG ELISAs were performed.</p><p><strong>Results: </strong>Overall, 130 dengue ICs and 301 HHCs were enrolled, with 91.7% (276/301) completing all follow-up visits. Baseline anti-DENV IgG showed prior dengue infections in 262/301 HHCs (87.0%). Fifty HHCs were excluded from the HHC infection analysis based on evidence of a DENV infection (viral load [VL], NS1, IgM, and IgG results) at enrollment. During follow-up, 2.0% of HHCs (5/251) had DENV infections based on virological parameters (DENV RNA and/or NS1 positivity), and anti-DENV IgG/IgM seroconversion was detected in 7.2% (18/251).</p><p><strong>Conclusions: </strong>This study demonstrated the operational feasibility of a dengue IC-HHC design for a Phase 2 trial.</p>\",\"PeriodicalId\":49328,\"journal\":{\"name\":\"Viruses-Basel\",\"volume\":\"17 6\",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197545/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Viruses-Basel\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/v17060859\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viruses-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/v17060859","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}
Dengue Infections Among Household Contacts of Symptomatic Index Cases: Implications for Community-Based Intervention Studies.
Background: Dengue is a global health concern, with half of the world's population at risk and no antiviral treatment available. This Phase 0 study investigated dengue infections among household contacts (HHCs) of dengue index cases (ICs) and assessed the feasibility of conducting a Phase 2 trial for a novel antiviral.
Methods: Participants were enrolled in Nha Trang, Vietnam, from April 2022 to February 2023. Dengue ICs were identified within 72 h of fever onset, and their healthy adult HHCs enrolled within 48 h. Blood samples and questionnaires were collected bi-weekly for four weeks, with a follow-up visit on day 40. DENV RT-qPCR, NS1, and anti-DENV IgM/IgG ELISAs were performed.
Results: Overall, 130 dengue ICs and 301 HHCs were enrolled, with 91.7% (276/301) completing all follow-up visits. Baseline anti-DENV IgG showed prior dengue infections in 262/301 HHCs (87.0%). Fifty HHCs were excluded from the HHC infection analysis based on evidence of a DENV infection (viral load [VL], NS1, IgM, and IgG results) at enrollment. During follow-up, 2.0% of HHCs (5/251) had DENV infections based on virological parameters (DENV RNA and/or NS1 positivity), and anti-DENV IgG/IgM seroconversion was detected in 7.2% (18/251).
Conclusions: This study demonstrated the operational feasibility of a dengue IC-HHC design for a Phase 2 trial.
期刊介绍：
Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the ''News and Views'' section. Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
